Nuvation Bio Inc., a global oncology company, has released a corporate presentation highlighting its recent achievements and ongoing projects in cancer treatment. The presentation details the approval of IBTROZITM (taletrectinib), a next-generation ROS1 inhibitor, for advanced ROS1+ non-small cell lung cancer (NSCLC) in both the U.S. and China. Additionally, Safusidenib, a brain-penetrant mIDH1 inhibitor, is entering pivotal studies for diffuse IDH1-mutant glioma. The company is also advancing NUV-1511, a clinical-stage drug-drug conjugate, in a Phase 1/2 study and has completed Phase 1 and Phase 1b studies for NUV-868, a BD2-selective BET inhibitor. With a robust cash balance and potential additional funding, Nuvation Bio is poised for further developments in its oncology programs. You can access the full presentation through the link below.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。